Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioRestorative Therapies (BRTX)
NASDAQ:BRTX
RESEARCH TOOLSreports
Holding BRTX?
Track your performance easily
BRTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.03 - $3.67
Previous Close$1.66
Volume76.50K
Average Volume (3M)55.26K
Market Cap
$11.49M
Enterprise Value-$3.11M
Total Cash (Recent Filing)$14.68M
Total Debt (Recent Filing)$83.58K
Price to Earnings (P/E)―
Beta1.35
Next Earnings
May 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding6,919,919
10 Day Avg. Volume28,322
30 Day Avg. Volume55,264
Standard Deviation21.99
R-Squared0.02
Alpha1.98
Financial Highlights & Ratios
Price to Book (P/B)1.06
Price to Sales (P/S)73.76
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-14.18
Enterprise Value/Gross Profit-21.33
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$12.00Price Target Upside622.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
BioRestorative Therapies News
PremiumCompany Announcements
BioRestorative Therapies Clarifies Press Release Usage in Filings
PremiumCompany Announcements
BioRestorative Therapies Issues Financial Update Notice
Bulls Say, Bears Say
Bulls Say
Metabolic DiseasesBioRestorative Therapies announced that it has entered into substantive discussions for a potential license agreement for the ThermoStem program in metabolic diseases like obesity.
New Product LaunchJet.AI Inc. reported first-quarter revenue that exceeded expectations and is optimistic about new software launches and a national jet card program.
Revenue GrowthExro Technologies Inc. is expected to see a significant increase in revenue in the second half of 2024.
Bears Say
CompetitionCoherus Biosciences, Inc. faces concerns due to competition and a lack of late-stage pipeline.
Financial PerformanceBioRestorative Therapies reported 2023 results with a net loss of ($14.4M) and net cash used in operations of ($6.4M).
Price TargetFactoring the dilution associated with the financing and pushing back timelines on commercialization of BRTX-100 to 2029, from 2028, the 12-month price target is lowered to $6, from $10.
---
Options Prices
Currently, No data available
---
Ownership Overview
36.81% Insiders
2.31% Mutual Funds
1.85% Other Institutional Investors
59.04% Public Companies and
Individual Investors
BRTX FAQ
What was BioRestorative Therapies’s price range in the past 12 months?
BioRestorative Therapies lowest stock price was $1.03 and its highest was $3.67 in the past 12 months.
What is BioRestorative Therapies’s market cap?
Currently, no data Available
When is BioRestorative Therapies’s upcoming earnings report date?
BioRestorative Therapies’s upcoming earnings report date is May 20, 2025 which is in 242 days.
How were BioRestorative Therapies’s earnings last quarter?
BioRestorative Therapies released its earnings results on Aug 13, 2024. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.57 by $0.07.
Is BioRestorative Therapies overvalued?
According to Wall Street analysts BioRestorative Therapies’s price is currently Undervalued.
Does BioRestorative Therapies pay dividends?
BioRestorative Therapies does not currently pay dividends.
What is BioRestorative Therapies’s EPS estimate?
BioRestorative Therapies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioRestorative Therapies have?
BioRestorative Therapies has 6,919,919 shares outstanding.
What happened to BioRestorative Therapies’s price movement after its last earnings report?
BioRestorative Therapies reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.57. Following the earnings report the stock price went down -0.709%.
Which hedge fund is a major shareholder of BioRestorative Therapies?
Currently, no hedge funds are holding shares in BRTX
---
BioRestorative Therapies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (622.89% Upside)
$12.00 (622.89% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.5%
Last 30 Days ▼ 14.4%
Last 30 Days ▼ 14.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.06%
12-Months-Change
Fundamentals
Return on Equity
-69.00%
Trailing 12-Months
Asset Growth
21.19%
Trailing 12-Months
Company Description
BioRestorative Therapies
Biorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. It intends to develop a laboratory, performing cellular characterization and culturing, therapeutic outcomes analysis, stem cell-related IP and stem cell collection and storage services. The company is developing the following scientific initiatives: brtxDISC Program offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures. The ThermoStem Program focuses on treatments for metabolic disorders and obesity and uses brown fat stem cells, which initial research indicates increased caloric burning and reduced glucose and lipid levels in the body. It also offers plant stem cell-based facial creams and products under the Stem Pearls brand. Biorestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.
---
BRTX Stock 12 Month Forecast
Average Price Target
$12.00
▲(622.89% Upside)
Technical Analysis
Best Analysts Covering BRTX
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
-30.89%
reiterated a buy rating last month
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -30.89% per trade.
---